Braun et al. [79] applied the CRISPR-Cas9 system to create CAR-T cells against EBV-infected Burkitt lymphomas by knocking out the TRAC (T cell receptor-α constant) gene and knocking in EBV glycoprotein 350 chimeric antigen receptor (gp350 CAR) or cluster of differentiation 19 (CD19) CAR templates via homology-directed repair. Here, CD19 is linked to Burkitt lymphoma.